Programme Book - British Society for Paediatric Endocrinology
Transcription
Programme Book - British Society for Paediatric Endocrinology
40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 7 - 9 November 2012 Including the CME Training Day on 7 November Leeds Town Hall, Leeds, UK Programme & Abstracts Book CPD approval has been sought from the Royal College of Paediatrics and Child Health of the UK for the main meeting. 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 7 - 9 November 2012 Including the CME Training Day on 7 November Leeds Town Hall, Leeds, UK www.bsped.org.uk Welcome to Leeds 2012 will be remembered for many anniversaries - the 200th birthday of Charles Dickens, the 100th anniversary of the Titanic tragedy, the Queen’s Diamond Jubilee, the British Olympics, and of course the Ruby anniversary of the British Society for Paediatric Endocrinology and Diabetes. It is a special year for paediatrics in Leeds too, as we officially opened the Leeds Children’s Hospital in the spring, and we are proud to be hosting this prestigious meeting in Yorkshire’s capital city. We have planned a diverse, informative and entertaining programme of events in the city which brought the world the likes of Peter O’Toole, Alan Bennett, Jane Tomlinson and Harry Ramsden (of fish and chips fame!) Leeds is a popular destination with lots to offer visitors. It is the only English city outside London with its own repertory theatre, opera house and ballet companies and the city is also home to the Royal Armouries and the Thackray medical museum. There are more listed buildings in Leeds than in any English city outside London, with highlights including the Victoria Quarter, Leeds Corn Exchange and Harewood House. The Rough Guide to Britain named shopping in Leeds as one of the top thirty things to do in the UK, and a great sporting heritage is built around worldfamous stadia like Headingley and Elland Road. Leodensians are justly proud of our venue for the fortieth meeting of the BSPED - the Leeds Town Hall. This stunning hybrid of classical Greek and baroque styles built by Charles Broderick between 1853 and 1858 houses a world famous organ, and is centrally located within walking distance of many of Leeds’ historical and cultural landmarks. Take the time to explore the nearby City Museum, Henry Moore Institute, Leeds Cathedral, or wander around the city markets - perhaps you could simply catch a film at the Leeds International Film Festival, which is showing many new releases at the Town Hall itself. LOCAL CONVENORS Sabah Alvi and Talat Mushtaq BENEFACTORS Ferring Pharmaceuticals Ltd Ipsen Ltd Merck Serono Novo Nordisk Ltd Pfizer Ltd Sandoz Biopharmaceuticals Sanofi Diabetes Also supported by BBI Healthcare Diasend/Aidera AB Eli Lilly & Company Ltd Roche Diabetes Care Siemens The 40th Annual BSPED meeting will start with a CME day on Wednesday 7th – with themes of pituitary and thyroid disorders. The following day the endocrine programme will focus on themes of genes, gender identity and, in the spirit of Olympic year, the impact of sport on health and disease. There will, as always, be opportunities for oral and poster presentation of new research, and a parallel endocrine nurse specialist session, but in response to feedback from our members, we are this year holding a single, fully integrated diabetes day with speakers from all disciplines - nursing, psychology and dietetics as well as paediatric and adult medicine-rather than parallel medical and nursing sessions. We have a list of nationally and internationally renowned speakers, and we aim to deliver a first class programme with talks to please all diabetes professionals, closing the meeting with a keynote lecture from one of the most renowned British diabetologists of our time. The conference dinner will be held at The Metropole Hotel, just a short walk from the Town Hall and city centre hotels. A highlight of the evening will be a short after dinner talk on the history and origins of the BSPED, delivered by one of the stalwarts of our Society…but you will need to attend to find out more! We look forward to welcoming you to Leeds for what promises to be a stimulating and educational anniversary meeting. Sabah Alvi and Talat Mushtaq 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 01 A61 A62 GENERAL INFORMATION M62 M621 Manchester & west M1 A653 M621 M1 Sheffield, LondonM1 & south A653 A61 M62 Date and place of Meeting The 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes and CME Training Day will be held on 7 - 9 November 2012 at Leeds Town Hall, The Headrow, Leeds, LS1 3AD Telephone: 0113 247 6647. NE ET T A 61 RE ST TH NT S T RE E OR N VI C A R LA N E R LA N E E A S TG A VIC A RE G E E G AT RIG RB PE 8 (M ) NEW TE Bus Station YO R W est Yorkshire Playhouse RD H CO U R T I T IN PO CR GN RE A E VE ST OW N C A LLS TH E H IG 1 A6 C A LL L N ET ST SO K R D RE LA N E GA TE N E VI L L E Leeds Station ST ST POSTER TOURS The poster session will take place during the lunch break on Thursday 9 November from 12.45-13:30. Category Poster Tour Leader(s) Adrenal Dr Li Chan Adrenal, Gonadal, DSD and reproduction Prof Faisal Ahmed Bone Dr Nick Shaw, Dr Jeremy Allgrove and Dr Paul Arundel Diabetes Dr Rakesh Amin and Dr Tabitha Randell Diabetes Nurse Mrs Marie Marshall and Ms Louise Collins Late effects of cancer treatment and Other / Misc Dr Liz Crowne Hyperinsulinism and Other / Misc Dr Indi Banerjee Other / Misc & Thyroid Dr Fiona Ryan Pituitary & growth Dr John Barton and Dr Sarah Ehtisham The Annual General Meeting of the BSPED The Annual General Meeting of the BSPED will be held on Thursday 9 November from 17.15-18.00 in the Victoria Hall. Nurse Sessions The Endocrine Nurse sessions will take place on Friday 9 November in the Albert Room. 02 A5 ST LL PS 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 4 Leeds Museum Discovery Centre [email protected] 7 R’ S HA O D B RIG G AT E TE OW Victoria Quarter BO AR H HI TH E H EAD R CENTRE B IS W IO N S T TRAVEL LODGE THE METROPOLE HOTEL A IRE S T A RO E Endocrine Nurses Business Meeting This will take place on Friday 9 November from 09:00 – 09:45 in the Albert Room. GENERAL INFORMATION 3 Leeds Industrial Museum [email protected] 6 TE CITY ST N PE LEEDS N G TO N LA ST DE W E LLI E UP RD PL O XFO TH E H E A D RO W A L B IO N S T LEEDS TOWN HALL IO N W AY M E RR PA R K R O W ) E A S T PA RA (M 58 M E RR W AD ) (M A T G E O RG E S T W E S TG A T E E IT E T C O O K RID G E S LA N P AY N E LA A 58 LEEDS CITY MUSEUM 2 Leeds City Museum [email protected] Social Programme O US T Badges Name badges will be provided at the registration desk on arrival and must be worn at all times for admission to the scientific sessions. Stewards will be checking badges on entrance to sessions. A E DH EY S A detailed programme can be found on page 7. PA R K OO RL BSPED CME Training Day The BSPED CME Training Day will take place on Wednesday 7 November 2012 from 09:30 – 16:30. This is the eighth annual BSPED CME day approved event and is part of a four year course aimed to cover the entire syllabus of paediatric endocrinology. This year’s course content will focus on pituitary and thyroid disorders. W E LV Hospital CL 1 Leeds Art Gallery [email protected] 5 Leeds Town Hall Welcome Reception [email protected] The welcome reception and opening LA RE C LA N D O N W AY CA Parking If travelling by car, there are a number of large car parks located nearby. The closest to Leeds Town Hall is Q-Park St Johns Centre, Merrion Street, LS2 8LQ. Hull & east M62 A 58 ( M ) GR Location Leeds Town Hall is conveniently located in the centre of Leeds, next to Leeds W E ST S T Central Library and Leeds City Art Gallery. It is a five minute walk from both the rail and bus stations and a 10 minute drive from the M1 and M62 motorways. Newcastle& north eas t symposium are generously supported by Pudsey Civic Hall Ferring Pharmaceuticals Ltd. These will [email protected] take place on Wednesday 7 November at 19:00 in the Leeds City Museum. All Temple Newsam House delegates are invited to join us. [email protected] 8 The Carriageworks Speakers Dinner [email protected] Supported by Novo Nordisk Ltd. The Speakers Dinner will take place on Wednesday 7 November at 19:45, by invitation only. Located at The Leeds Club, 3 Albion Place, Leeds, West Yorkshire LS1 6JL. Conference Dinner The Conference Dinner will take place at 20:00 on Thursday 8 November 2012 at The Metropole Hotel, King Street, Leeds, West Yorkshire LS1 2HQ. A three course dinner will follow along with entertainment. There may be a limited number of tickets available for purchase, please check at the registration desk. Exhibitors and Sponsors The exhibition is located in The Sullivan Room, Elgar Room, Walton Room and along the rear corridor of Leeds Town Hall. Exhibiting companies at this meeting are: Diasend/Aidera AB, Eli Lilly & Company Ltd, Ferring Pharmaceuticals Ltd, Ipsen Ltd, Merck Serono, Novo Nordisk Ltd, Pfizer Ltd, Roche Diabetes Care, Sandoz Biopharmaceuticals, Sanofi Diabetes. We would also like to thank Novo Nordisk Ltd for the speakers dinner. Disabled Facilities Leeds Town Hall is fully accessible with a lift to the first floor, disabled toilet facilities and disabled parking next to the entrance. Taxis A list of taxi numbers can be found at the registration desk. Benefactors We are grateful to the following benefactors for their support of the BSPED: Ferring Pharmaceuticals Ltd Ipsen Ltd Merck Serono Novo Nordisk Ltd Pfizer Ltd Sandoz Biopharmaceuticals Sanofi Diabetes Catering A packed lunch will be available on each day of the meeting, along with refreshments during designated breaks in the Exhibition Halls (The Sullivan Room, Elgar Room and Walton Room). Prayer Room This is located in the Waterman Room. Symposium Ferring Pharmaceuticals are holding a satellite symposium entitled Regulation of Salt and Water Balance on Wednesday 7 November 2012 from 17:30 – 19:00 in Leeds City Museum, Millennium Square, Leeds, West Yorkshire LS2 8BH. All delegates are invited to attend this satellite symposium and entrance is included in the registration fee. Further details can be found on page 8. CPD approval CPD approval has been sought for this meeting. 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 03 DAy PLAnNer WEDNESDAY 7 November 2012 VICTORIA Hall THURSDAY 8 November 2012 Day PLANNER Leeds City Museum 07.30 VICTORIA Hall 07.30 CME Training Day MAIN MEETING 08.00 08.00 08.30 08.30 09.00 09.00 09.30 10.00 10.30 11.00 12.00 TEA & COFFEE 11.00 11.30 The surgical management of pituitary tumours Symposium 1 Gender Identity Development Care and Controversies 12.00 Pituitary cases x2 13.00 13.00 14.30 Oral Communications 1 10.30 Causes, diagnosis and management of pituitary dysfunction 12.30 14.00 MAIN MEETING WELCOME 10.00 Physiology and developmental disorders of the pituitary 12.30 13.30 REGISTRATION OPENS 09.30 REGISTRATION Albert Hall TEA & COFFEE 11.30 ALBERT ROOM LUNCH AND POSTER TOUR LUNCH 13.30 Thyroid - physiology and developmental biology 14.00 Hyperthyroidism and its management Symposium 2 Controversies in Paediatric Endocrinology 14.30 Oral Communications 2 15.00 Hypothyroidism and its management 15.00 15.30 15.30 TEA & COFFEE 16.00 TEA & COFFEE 16.00 Thyroid cases x2 16.30 16.30 CLOSE 17.00 17.30 18.00 REGISTRATION Leeds City Museum, Leeds Ferring Pharmaceuticals Satellite Symposium Leeds City Museum, Leeds Symposium 3 The Olympiad! 17.00 17.30 BSPED Annual General Meeting 18.00 Regulation of Salt and Water Balance 18.30 19.00 19.30 18.30 Welcome Reception Leeds City Museum, Leeds 20.00 04 19.00 19.30 20.00 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes Pre-Dinner Welcome Reception Conference dinner 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 05 DAY PLANNER FriDAY 9 November 2012 VICTORIA Hall ALBERT ROOM MAIN MEETING Endocrine Nurse Day 07.30 08.00 08.30 09.00 09.30 10.00 Oral Communications 3 10.30 11.00 Registration Opens Registration Opens 09:55 - 10:00 Welcome Paediatric Endocrine Nurses Business Meeting (incorporating relaunch of the BSPED GH Audit) 10:00 - 11:00 CME Session 1 Welcome Ipsen Award Winners TEA & COFFEE TEA & COFFEE Oral Communications 4 Oral Communications 5 11.30 Nurse Session 1 12.00 12.30 13.00 13.30 14.00 14.30 15.00 Symposium 5 Diabetes and Education NOVO NORDISK AWARD WINNER Case presentation: endocrinology in sport Nurse Session 2 BSPED Prizes LUNCH & POSTERS S1 Physiology and developmental disorders of the pituitary M Dattani (London) S2 Causes, diagnosis and management of pituitary dysfunction M Maghnie (Genoa, Italy) 11:00 - 11:30 Tea & Coffee 11:30 - 12:00 CME Session 2 S3 The surgical management of pituitary tumours S Sinha (Sheffield) 12:00 - 13:00 Pituitary cases x2 13:00 - 13:45 Lunch 13:45 - 15:30 CME Session 3 LUNCH Symposium 6 Diabetes and Sport Keynote Lecture 15.30 16.00 CME training Day - Pituitary and Thyroid VICTORIA HALL 09:30 - 16:30 REGISTRATION OPENS Symposium 4 Hot topics In Diabetes WEDNESDAY 7 November 2012 SCIENTIFIC PROGRAMME CLOSE 13:45S4 Thyroid - physiology and developmental biology N Schoenmakers (Cambridge) 14:15S5 Hyperthyroidism and its management T Cheetham (Newcastle) 14:45 S6 Hypothyroidism and its management M Donaldson (Glasgow) 15:30 - 16:00 Tea & Coffee 16.30 16:00 - 16:30 17.00 16:30 17.30 Thyroid cases x2 Close of meeting 18.00 18.30 19.00 19.30 20.00 06 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 07 SCIENTIFIC PROGRAMME WEDNESDAY 7 November 2012 THURSDAY 8 November 2012 SCIENTIFIC PROGRAMME Leeds City Museum Main meeting – VICTORIA Hall 16:45 - 19:45 Registration Leeds City Museum, Leeds 17:30 - 19:00 Ferring Pharmaceuticals Satellite Symposium Leeds City Museum, Leeds Regulation of Salt and Water Balance Chair: T Cheetham (Newcastle upon Tyne) Diabetes Insipidus and Pituitary Stalk Abnormalities M Maghnie (Genoa, Italy) Other Forms of Salt and Water Disturbance S Ball (Newcastle) 19:00 - 19:45 Welcome Reception Leeds City Museum, Leeds 08 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 08:15 - 08:45 Registration Opens 08:45 - 09:00 Welcome 09:00 - 10:30 Oral Communications 1 Chairs: S Kanumakala (Brighton) & L Metherell (London OC1.1 Iodine status in UK pregnant women and implications for fetal brain development Presenter: S Bath (Surrey) S Bath, C Steer, J Golding, P Emmett, M Rayman OC1.2 Disease- and treatment-related factors implicated in late neuroendocrine morbidity after paediatric optic pathway gliomas: a preliminary multivariate analysis of 96 patients treated over 30 years Presenter: HW Gan (London) HW Gan, H Spoudeas OC1.3 Potential novel insights into the control of the feto- placental unit by kisspeptin Presenter: H Katugampola (London) H Katugampola, L Dunkel, P King, J Achermann, A Duncan, U Sankilampi, H Storr OC1.4 Skeletal effects of hypothyroidism are mediated by thyroid hormone receptor alpha Presenter: M Cheung (London) M Cheung, A Boyde, H Evans, D Bassett, G Williams OC1.5 Ethnic differences in vascular growth factor levels in early life in relation to arterial stiffness in The Manchester Heart And Growth Study Presenter: S Khan (Manchester) S Khan, S Anderson, A Whatmore, P Pemberton, A Vyas, K Cruikshank, P Clayton OC1.6 A novel syndrome characterized by hypothalamic hormonal insufficiency, neonatal seizures, congenital abnormalities of the kidneys and urinary tract and obesity due to mutation in a gene regulating hypothalamic development Presenter: E Webb (London) E Webb, D Kelberman, A Al Mutair, C Andoniadou, C Bacchelli, E Chanudet, R Kleta, F Lescai, E Stupka, P Beales, J Sowden, JP Martinez, M Dattani 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 09 SCIENTIFIC PROGRAMME THURSDAY 8 November 2012 THURSDAY 8 November 2012 SCIENTIFIC PROGRAMME OC1.7 Novel therapies herald novel diseases: The first paediatric case series of Graves’ immune reconstitution disease Presenter: A Sinha (Newcastle upon Tyne) A Sinha, M Abinun, T Cheetham OC1.8 Loss-of-Function Mutations in IGSF1 Cause a Novel, X-Linked Syndrome of Central Hypothyroidism and Testicular Enlargement Presenter: N Schoenmakers (Cambridge) N Schoenmakers, B Bak, Y Sun, P van Trotsenburg, W Oostdijk, P Voshol, L Persani, T Davis, P le Tissier, N Gharavy, N Appelman-Dijkstra, A Pereira, J den Dunnen, M Breuning, R Hennekam, V Krishna Chatterjee, M Dattani, D Bernard, JM Wit 10:30 - 11:00 Tea & Coffee 14:30 - 15:30 Oral Communications 2 Chair: P Dimitri (Sheffield) 11:00 - 12:00 Symposium 1 - Gender Identity Development - Care and Controversies Chairs: S Alvi (Leeds) & G Butler (London) 11:00S7 The development of sexual identity and understanding of GID P Carmichael (London) 11:30S8 12:00 - 13:30 Gender reassignment surgery in GID J Bellringer (London) Lunch 12:45 - 13:30 Poster Tour 13:30 - 14:30 Symposium 2 - Controversies in Paediatric Endocrinology Chairs: M Dattani (London) & H Storr (London) 13:30S9 Growth Hormone in transition M Maghnie (Genoa, Italy) 14:00S10 MEN Syndromes- genetics and the ethics of screening C Chu (Leeds) 10 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes OC2.1 Assessment of adrenal function in female to male adolescents with Gender Identity Dysphoria (GID). Presenter: M Ajzensztejn (London) M Ajzensztejn, M Gopalakrishnamoorthy, A Dawnay, R Viner, C Brain, G Butler OC2.2 Deficiency of the triple A syndrome gene product, ALADIN, renders human adrenal cells susceptible to oxidative stress with subsequent impact on steroidogenesis Presenter: R Prasad (London) R Prasad, A Clark, H Storr OC2.3 Does Vitamin D modulate mitochondrial oxidative phosphorylation? Presenter: A Sinha (Newcastle upon Tyne) A Sinha, S Ball, K Hollingsworth, T Cheetham OC2.4 Prenatal dexamethasone for treatment of congenital adrenal hyperplasia: a possible association with late gestational fetal demise in two cases. Presenter: A Peacock (Leeds) A Peacock, I Abbey, S Alvi, C Bennett, J Dwyer, T Glanville, T Mushtaq OC2.5 Abnormal neurological and developmental outcomes in children with persistent and spontaneously resolving congenital hyperinsulinism Presenter: B Avatapalle (Manchester) B Avatapalle, S Shah, M Pryce, J Nicholson, L Rigby, L Caine, M Didi, S Ehtisham, L Patel, M Skae, R Padidela, I Banerjee, P Clayton OC2.6 Childhood body composition is associated with maternal plasma polyunsaturated fatty acids status in late pregnancy Presenter: R Moon (Southampton) R Moon, NC Harvey, G Ntani, JH Davies, HM Inskip, K Godfrey, EM Dennison, P Calder, C Cooper OC2.7 Growth, GH-IGF-I status and response to r-hGH therapy in 3-M Syndrome, related to mutation status Presenter: F Sakhinia (Manchester) F Sakhinia, D Hanson, P Murray, J Kirk, T Cole, M Skae, I Banerjee, R Padidela, L Patel, P Clayton 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 11 SCIENTIFIC PROGRAMME THURSDAY 8 November 2012 OC2.8 Genetic screening in a large cohort of patients with congenital hypopituitarism; current knowledge and future directions Presenter: KS Alatzoglou (London) KS Alatzoglou, JPG Turton, D Kelberman, MJ McCabe, LC Gregory, EA Webb, DEG McNay, KS Woods, A Mehta, MT Dattani OC2.9 Growth hormone (GH) neuro-secretory dysfunction following traumatic brain injury (TBI) in childhood Presenter: N Daskas (Bristol) N Daskas, P Sharples, E Crowne OC2.10 When is it justifiable to await venous thyroid function tests before starting thyroxine treatment in infants referred with capillary TSH elevation? Presenter: T Pokrovska (Glasgow) T Pokrovska, J Jones, G Shaikh, M Donaldson 15:30 - 16:00 Tea & Coffee 16:00 - 17:00 Symposium 3 - The Olympiad! Chairs: T Mushtaq (Leeds) & J Wales (Sheffield) 16:00S11 Beyond reasonable doubt – catching the GH cheats R Holt (Southampton) 16:30S12 17:15 - 18:00 Physical activity and athletic training in children and adolescents A Rogol (Virginia, USA) 19:15 - 20:00 Pre-Dinner Welcome Reception 20:00 - BSPED Annual General Meeting Conference Dinner FRIDAY 9 November 2012 SCIENTIFIC PROGRAMME Main meeting – VICTORIA Hall 08:15 - Registrations Opens 09:00 - 10:00 Symposium 4 - Hot topics In Diabetes Chairs: F Campbell (Leeds) & T Barrett (Birmingham) 09:00S13 Improving outcomes in teenagers and young adults with Type 1 diabetes S Heller (Sheffield) 09:30S14 10:00 - 10:30 Continuous age appropriate structured education for children and young people with diabetes K Lange (Hanover, Germany) Oral Communications 3 Chairs: C Acerini (Cambridge) & N Wright (Sheffield) OC3.1 HbA1c league tables: Does selection policy encourage foul play to support promotion to the “premier league”? Presenter: M Wassef (Sheffield) M Wassef, C Elder, N Wright OC3.2 Audit of management of diabetic ketoacidosis in children Presenter: A Shetty (Cardiff) J A Shetty, J Warner OC3.3 Quality of Life and HbA1c outcomes in children and young people commencing insulin pump therapy Presenter: J Cropper (London) J Cropper, L Kanchi, M Ford-Adams, T Hulse, C Buchanan, E Barker OC3.4 Continuous Glucose Monitoring - Are there more barriers than benefits? Presenter: C Gelder (Leeds) C Gelder OC3.5 Childhood Type I diabetes education at time of diagnosis- what patients want to know Presenter: E Holloway (Chertsey) E Holloway, D Wilkinson, Y Squire, J Holzmann, A Lyddall, S Bahl 10:30 - 11:00 Tea & Coffee 11:00 - 12:00 Oral Communications 4 Chairs: C Acerini (Cambridge) & N Wright (Sheffield) OC4.1 Metformin in Obese Children and Adolescents: the MOCA trial Presenter: D Kendall (Manchester) D Kendall, R Amin, T Barrett, P Dimitri, F Ivison, M Kibirige, V Mathew, K Matyka, A McGovern, H Stirling, L Tetlow, A Vail, J Wales, N Wright, P Clayton, C Hall 12 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 13 SCIENTIFIC PROGRAMME FriDAY 9 November 2012 OC4.2 Patterns of presentation and initial management of type I diabetes mellitus in the UK: the Early Care Survey Presenter: O Lokulo-Sodipe (Southampton) O Lokulo-Sodipe, RJ Moon, J Edge, JH Davies OC4.3 White UK children are older, more obese and more insulin resistant than non-White UK children at diagnosis of type 2 diabetes: baseline results of the UK national Type 2 diabetes cohort Presenter: T Barrett (Birmingham) T Barrett, Z Gray, E Ilsley, C Cotter, L Makusha, A Ford, K Turner, J Heywood, A Barnett, D Dunger, J Hamilton-Shield, J Wales OC4.4 Vacuolar-type H+-ATPase V1A subunit is a molecular partner of Wolfram syndrome 1 (WFS1) protein, which regulates its stability and expression Presenter: S Gharanei (Birmingham) S Gharanei, M Zatyka, D Astuti, J Fenton, A Sik, Z Nagy, T Barrett OC4.5 The effect of insulin intensification on glycaemic control and lipid levels in children and young persons with type 1 diabetes differs in relation to ethnic group Presenter: R Dias (Birmingham) R Dias, F Brown, C Wyatt, S Cheema, J Allgrove, R Amin 12:00 - 12:45 Symposium 5 - Diabetes AND Education Chairs: C Gelder (Leeds) & G Parfitt (Newport) S15 NOVO NORDISK AWARD WINNER Structured Knowledge and Information Programme- the SKIP course N Lovell (Bristol) S16 How paediatric diabetes nurse specialists support schools M Marshall (Manchester) 12:45 - 13:00 BSPED Prizes 13:00 - 14:00 Lunch 14:00 - 15:00 Symposium 6 - Diabetes and Sport Chairs: F Annan (Liverpool) & J Edge (Oxford) 14:00S17 Physiology of exercise and endurance sport in type 1 diabetes R Andrews (Taunton) FriDAY 9 November 2012 SCIENTIFIC PROGRAMME Endocrine Nurse Day – Albert ROOM Generously supported by Sandoz Biopharmaceuticals 08:30 - 09:00 Registration Opens 09:00 - 09:55 Paediatric Endocrine Nurses Business Meeting (incorporating relaunch of the BSPED GH audit) 09:55 - 10:00 Welcome Chairs: J Walker (Leeds) & A Whitehead (Leeds) 10:00 - 10:30 Ipsen Award Winners 10:00S20 Congenital hyperinsulinism: The American experience L Rigby (Manchester) 10:15S21 The DSD Clinic N Nicoll (Bristol) 10:30 - 11:00 Tea & Coffee 11:00 - 11:40 Oral Communications 5 OC5.1 Adolescent Transition Clinic: A review of the young person’s self-confidence and future concerns. Presenter: A Whitehead (Leeds) A Whitehead, J Walker, T Mushtaq, NS Alvi OC5.2 Comparison of patient experiences of the glucagon and insulin pituitary provocation tests: time for a reappraisal Presenter: H Katugampola (London) H Katugampola, C Bulwer, HA Spoudeas OC5.3 A comparison of patient’s preferences for attributes of growth hormone delivery devices: children starting versus children established on growth hormone treatment Presenter: S How Yaw (Leeds) S How Yaw, T Mushtaq, NS Alvi, J Walker, A Whitehead OC5.4 The role of the paediatric endocrine nurse in supporting the information needs of girls with Turner syndrome and their parents Presenter: J Collin (Manchester) J Collin 14:30S18 Optimising sports performance in Type 1 diabetes G Regan (Newport) 15:00 - 15:45 Keynote Lecture Chair: J Gregory (Cardiff) 15:00S19 Insulin pumps and continuous monitoring: evidence for their role in the management of diabetes J Pickup (London) 15:45 - 15:50 Closing remarks 14 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 15 SCIENTIFIC PROGRAMME FriDAY 9 November 2012 11:40 - 12:20 FriDAY 9 November 2012 SCIENTIFIC PROGRAMME and Nurse Session 1 11:40S22 The Bare Bones P Arundel (Sheffield) 12:20 - 12:30 Case Presentation: Endocrinology in Sport 12:20S23Running High R Mayers (Bristol) 12:30 – 13:15 Nurse Session 2 12:30 S25 Egg and Ovarian Tissue Preservation. What Can we Offer to Preserve Fertility Options for the Future? S Nicholas (Leeds) ZN/271/2010/UKc. Date of preparation of item: June 2011. Made for each other 16 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes ZOMACTON® 10mg/ml Powder and Solvent for Solution for Injection in Prefilled Syringe. ZOMACTON® 4mg INJECTION Please consult the full Summary of Product Characteristics before prescribing. Zomacton® 10mg/ml Injection (Somatropin, INN). Zomacton® 4mg Injection (Somatropin, INN). Presentation: Zomacton 10mg/ml: Each vial contains 10mg Somatropin and is supplied with a prefilled syringe of solvent for solution for injection. Zomacton 4mg: Each vial contains 4mg Somatropin and is supplied with an ampoule of diluent Uses: The long-term treatment of children who have growth failure due to inadequate secretion of growth hormone and for the long-term treatment of growth retardation due to Turner’s syndrome confirmed by chromosome analysis. Dosage and administration: Zomacton Injection is administered as a subcutaneous injection. Growth Hormone Deficiency: The dosage and schedule of administration should be individualised for each patient. Generally a dose of 0.17 - 0.23mg/kg bodyweight per week divided into 6 - 7 subcutaneous injections is recommended (corresponding to a daily injection of 0.02 - 0.03mg/kg bodyweight). Turner’s Syndrome: Generally a dose of 0.33 mg/kg bodyweight per week divided into 6 - 7 s.c. injections is recommended (corresponding to a daily injection of 0.05 mg/kg/ bodyweight). The required dose Zomacton 10mg is administered with a ZOMAJET VISION X needle free device. The required dose Zomacton 4mg is administered with a ZOMAJET 2 VISION needle free device. Both forms of Zomacton may be administered using conventional needle and syringe. Contraindications: Use in children with closed epiphyses. Patients with acute illness suffering complications. Evidence of tumour activity or if anti-tumour therapy is ongoing. Known sensitivity to somatropin or any excipient. Zomacton 4mg injection must not be given to premature babies or neonates as the solvent contains benzyl alcohol. Zomacton Injection should not be used during pregnancy or lactation. Special warnings and precautions for use: Therapy should be supervised by an appropriately qualified and experienced clinician. Very rare cases of myositosis have been observed and may be due to the metacresol preservative in Zomacton 10mg/ml. If a patient using Zomacton 10mg/ml develops myalgia or disproportionate injection site pain, Zomacton 4mg injection should be used. Patients should be observed for evidence of glucose intolerance. Use with caution in children with diabetes mellitus or a familial predisposition to the disease. In children with growth hormone deficiency and diabetes mellitus, glycaemic control must be monitored and insulin needs adjusted accordingly. Patients with growth hormone deficiency secondary to an intracranial lesion should be monitored frequently. Therapy should be discontinued if progression or recurrence of the lesion occurs. Fundoscopic examination for papilloedema is recommended at the initiation and periodically during the course of treatment, especially if the patient reports recurrent headache, visual problems, nausea and/or vomiting which may indicate intracranial hypertension. Hypothyroidism may develop during treatment with growth hormone and inadequate treatment may prevent optimal response to growth hormone. Growth failure due to Prader Willi syndrome is contraindicated unless GH deficiency is diagnosed. Zomacton should be discontinued at renal transplantation. Signs of scoliosis should be monitored during treatment. Caution must be taken in patients with central subclinical hypothyroidism and in patients on thyroxin replacement therapy. Slipped capital femoral epiphysis may occur, a patient developing a limp or hip or knee pain should be evaluated by a physician. The safety of ongoing GH replacement in patients with critical illness has not been determined and benefit needs to weighed against risk. Side effects: Please consult the full Summary of Product Characteristics for further information about side effects. Injection site reactions and transient headache have been reported. Infrequently, a slight transient oedema may occur during treatment. Formation of antibodies against somatropin have been observed but binding capacity of these is low and no clinical changes have been reported. Hypoglycaemia is a common event. Leukaemia has been reported very rarely, the rate is similar untreated patients. In rare cases a benign intracranial hypertension, and diabetes mellitus have been reported. Symptoms usually are headache, nausea and/or vomiting and visual problems. Pharmaceutical precautions: Zomacton 10mg/ml: Store at 2 - 8*C and protect from light. After reconstitution it is stable for 28 days when stored upright in the refrigerator at 2 - 8*C and protected from light. Zomacton 4mg: Store at 2 - 8*C and protect from light. After reconstitution it is stable for 14 days when stored in the refrigerator at 2 - 8*C and protected from light. Legal category: POM. Package quantity: Zomacton 10mg/ml: Carton containing one vial of Zomacton® 10mg/ml Injection and one prefilled syringe of solvent for solution for injection. Zomacton 4mg: Carton containing one vial of Zomacton 4mg Injection and one ampoule of diluent. Basic NHS price: Zomacton 10mg/ml: £199.23, Zomacton 4mg: £79.69. Product Licence number: Zomacton 10mg/ml: PL 3194/0104. Zomacton 4mg: PL 3194/0052. Product Licence holder: Ferring Pharmaceuticals Ltd., Drayton Hall, Church Road, West Drayton, UB7 7PS. Date of preparation: March 2011. Zomacton is a registered trade mark. Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to: Medical Information, Ferring Pharmaceuticals Ltd., Drayton Hall, Church Road, West Drayton, UB7 7PS. Tel: 0844 931 0050. Email: [email protected]. Ferring Pharmaceuticals Ltd., Drayton Hall, Church Road, West Drayton, UB7 7PS. Telephone: 0844 931 0050, Fax 0844 931 0057 www.ferring.co.uk ZomaJet® and Zomacton® are registered trademarks. 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 17 Novo Nordisk was founded in 1923 out of a passion to help people with diabetes. With our strong commitment to patients and by offering the largest portfolio of products in the industry, we look to defeat diabetes by improving awareness, prevention, detection, and treatment of this chronic disease. The Greener Choice N In addition, Novo Nordisk has a leading position within areas such as growth hormone therapy, as well as haemostasis management and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. For more information, please visit: www.novonordisk.co.uk UK/NC/0910/0010 Date of preparation September 2010 Ipsen is now working with international conservation organisation, the World Land Trust (WLT) to protect and reforest threatened ecosystems through tree planting, initially in Brazil and Ecuador. Ipsen is also promoting WLT’s work to help improve understanding of the world’s most biologically important habitats. h ie y fo r a h e alt r to i ng da mo r ro w THE G G ro w to ICE HO ENER C RE October 2012 BSPED – UK/NUT08376 Refer to the Summary of Product Characteristics for full information, particularly in relation to dosing, precautions and side effects, before prescribing. Abbreviated Prescribing Information for Omnitrope (somatropin). Produced by recombinant DNA technology in Escherichia coli. Presentation: 5 mg/1.5 ml (15IU) solution for injection and 10 mg/1.5 ml (30IU) solution for injection. Indications: Children: growth disturbance due to insufficient secretion of growth hormone (pGHD) or associated with Turner syndrome (TS) or associated with chronic renal insufficiency (CRI) or in short children/adolescents born small for gestational age (SGA), with a birth weight and/or length below -2 standard deviations, who failed to show catch-up growth by 4 years of age or later. Prader-Willi Syndrome (PWS): for improvement of growth and body composition. Adults: pronounced growth hormone deficiency (GHD). Dosage and Administration: Subcutaneous injection. Rotate sites to avoid lipoatrophy. The maximum recommended daily dose should not be exceeded. pGHD: 0.025 - 0.035 mg/kg body weight/day. PWS: 0.035 mg/kg body weight per day, do not exceed 2.7 mg/day. TS: 0.045 - 0.050 mg/kg body weight/day. CRI: 0.045 - 0.050 mg/kg body weight/day. Higher doses can be needed if growth velocity is too low. SGA: 0.035 mg/kg body weight/day until final height reached. Adult GHD: Start with low dose 0.15 - 0.3 mg/day. Elderly: Experience in patients above 60 years is limited. Renal impairment: In CRI, renal function should be below 50 percent of normal before institution of therapy. Discontinue at renal transplantation. Contraindications: Hypersensitivity to somatropin or excipients; growth promotion in patients with closed epiphyses; acute critical illness following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory ® NOTES Grow with us failure or similar conditions. Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting GH therapy. Treatment should be discontinued if there is evidence of tumour growth. Precautions: May induce a state of insulin resistance and hyperglycaemia: observe for glucose intolerance. In patients with existing diabetes mellitus, anti-diabetic therapy may require adjustment. Monitor thyroid function. Optimise corticosteroid therapy prior to initiation. Signs of relapse of malignant disease should be monitored for. Slipped epiphyses of the hip may occur more frequently. Monitor for benign intracranial hypertension. Refer paediatric patients with PWS and concomitant risk factors for thorough evaluation due to risk of fatality; monitor weight and restrict calorie intake; monitor for scoliosis. Not recommended to initiate treatment in SGA patients near onset of puberty. In acute, critically ill adult patients, somatropin may increase mortality. Omnitrope 5 mg/1.5 ml solution for injection: includes benzyl alcohol and must not be given to premature babies or neonates. May cause toxic and anaphylactoid reactions in infants and children up to 3 years old. Interactions: Somatropin may increase the clearance of compounds resulting in lower plasma levels known to be metabolised by cytochrome P450 isoenzymes, especially CYP 450 3A4 e.g. sex steroids, corticosteroids, anticonvulsants and ciclosporin. Clinical significance is unknown. Pregnancy: Do not use in pregnancy. Lactation: Use with caution. Side effects: Common: formation of antibodies; common in adults, uncommon in children paraesthesia, stiffness in the extremities, arthralgia, myalgia, peripheral oedema. Common in children - transient local injection site reactions. Rare: Diabetes mellitus Type II, benign intracranial hypertension. Very rare: leukaemia. Pack sizes/cost: (excl VAT): 5 mg/1.5 ml, 5 vial pack - £433.82. 10 mg/1.5 ml, 5 vial pack £867.64. Legal Category: CD Anab POM. MA Holder: Sandoz GmbH, Biochemiestrasse 10, A-6250 Kundl, Austria. Distributed by Sandoz Ltd, Frimley Business Park, Camberley, Surrey, GU16 7SR. MA No: 5mg/1.5ml -EU/1/06/332/005, 10mg/1.5ml - EU/1/06/332/008. UK/MKT/OMN/120028 April 2012. A lifetime commitment ® Convenience and 1 simplicity Well-established 2 safety profile Least expensive somatropin 3 on the NHS Proven long-term 2 efficacy Established 2 bioquivalence Adverse events should be reported. Reporting forms and Information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Sandoz Ltd, 01276 698020 or [email protected]. 25 years in Endocrinology Individualised Treatment – Our focus for the future References: 1. Data on file, 2008; Sandoz Int. 2. Romer T et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. Horm Res. 2009; 72(6): 359-69. 3. MIMS October 2012. Date of preparation: October 2012. Code: UK/MKT/OMN/12-0073. Specialty Care Endocrine Grow with us Biopharmaceuticals Date of preparation: August 2012 GEN 3402 NOTES NOTES . This meeting has in part, been organised and funded by SANOFI Date of Preparation: October 2012 GBIE.GLA.11.10.22 22 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes PRESCRIBING INFORMATION - UK AND IRELAND Please refer to the Summary of Product Characteristics for further information. SAIZEN® 8 mg click.easy®powder and solvent for solution for injection SAIZEN 5.83 mg/ml solution for injection SAIZEN 8 mg/ml solution for injection Somatropin (recombinant human growth hormone) Presentation: SAIZEN® 8 mg click.easy®powder and solvent for solution for injection: Each multi-dose vial of SAIZEN® contains Somatropin 8 mg as a powder, accompanied by a cartridge of solvent containing 1.37 ml of 0.3% w/v metacresol in water for injections. SAIZEN 5.83 mg/ml solution for injection: Each cartridge contains 1.03 ml solution (6 mg somatropin) SAIZEN 8 mg/ml solution for injection: Each cartridge contains either 1.50 ml solution (12 mg somatropin), or 2.50 ml solution (20 mg somatropin), Indications: The treatment of growth failure in children caused by decreased or absent secretion of endogenous growth hormone; Growth failure in girls with gonadal dysgenesis (Turner Syndrome); Growth failure in prepubertal children due to chronic renal failure; Growth disturbance (current height SDS < -2.5 and parental adjusted height SDS < -1) in short children born small for gestational age (SGA) with a birth weight and/or length below – 2 SD, who failed to show catch-up growth (HV SDS < 0 during the last year) by 4 years of age or later; Replacement therapy in adults with pronounced growth hormone deficiency who must also fulfil the following criteria: Childhood onset: Patients diagnosed as growth hormone deficient during childhood must be re-tested and deficiency confirmed before start of replacement therapy with Saizen. Adult onset: Patient must be growth hormone deficient as a result of hypothalamic or pituitary disease and have at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted before treatment with growth hormone. Dosage and Administration: Saizen 8mg click.easy, Saizen 5.83 mg/ml solution for injection and Saizen 8 mg/ml solution for injection when used with the appropriate auto-injector are all for multiple dose use. The dose for each is given by subcutaneous administration and under no circumstances should the daily dose be exceeded. It is recommended that Saizen is administered at bedtime. Growth failure due to inadequate secretion of endogenous growth hormone: 0.7-1.0 mg/m2 body surface area (BSA) per day or 0.025-0.035 mg/kg body weight per day. Growth failure due to Turner Syndrome: 1.4 mg/m2 BSA per day or 0.045-0.050 mg/kg body weight per day. Concomitant therapy with non-androgenic anabolic steroids can enhance growth response. Growth failure in prepubertal children due to chronic renal failure: 1.4 mg/m2 BSA per day, approximately equal to 0.045-0.050 mg/kg body weight per day. Growth failure in short children born small for gestational age (SGA): The recommended daily dose is 0.035 mg/kg body weight (or 1 mg/m2/day, equal to 0.1 IU/kg/day or 3 IU/m2/day). Treatment should be discontinued when the patient reaches a satisfactory adult height or the epiphyses are fused. For growth disturbance in short children born SGA treatment is usually recommended until final height is reached. Growth Hormone Deficiency in adults: Low daily doses of 0.15-0.3 mg are recommended initially. Dosage should be adjusted stepwise, controlled by Insulin-like Growth Factor 1 (IGF-1) values. The lowest efficacious dose is recommended, this seldom exceeds 1.0 mg/day. In older or overweight patients, Date of Preparation: October 2012 lower doses may be necessary. Contraindications: Epiphyseal fusion in children. Somatropin must not be used in patients with active tumours. Intracranial tumours must be inactive and anti-tumour therapy must be completed prior to starting GH therapy. Treatment should be discontinued if there is evidence of tumour growth. Known hypersensitivity to any ingredients in the injection or solvent; critically ill patients. Treatment should be discontinued at the time of renal transplantation. Precautions: Treatment should be carried out under regular specialist medical supervision. Patients with intra or extracranial neoplasia in remission or those with growth hormone deficiency secondary to an intracranial tumour should be examined frequently whilst receiving growth hormone. Cases of leukaemia have been reported in growth hormone deficient (GHD) patients. However a causal relationship to somatropin has not been established. Somatropin may reduce insulin sensitivity so patients should be monitored for evidence of glucose intolerance. Diabetic patients may need to adjust insulin doses after somatropin treatment is initiated and regular glucose monitoring may be required. Treatment should be discontinued in cases of proliferative retinopathy. Pregnancy: Not recommended during pregnancy or in women of child-bearing potential not using contraception. Lactation: Caution should be exercised when somatropin is administered to breast feeding women. Thyroid function tests should be monitored in all patients. In case of severe or recurrent headache, visual problems, nausea and/or vomiting, funduscopy for papilloedema is recommended. If papilloedema is confirmed a diagnosis of benign intracranial hypertension should be considered and growth hormone discontinued. If growth hormone treatment is restarted careful monitoring for signs of benign intracranial hypertension is required. In children with growth failure secondary to chronic renal failure, renal function should have decreased to below 50% of normal before treatment. Conservative treatment for renal insufficiency should have been established and maintained during treatment. During treatment patients should be examined for progression of renal osteodystrophy. Growth spurts may increase risk of joint related problems e.g. slipped capital femoral epiphysis. Physicians and parents should be alert to the development of a limp and knee or hip pain in children treated with somatropin. In patients with chronic renal failure hip x-ray is recommended prior to starting somatropin therapy. Testing for antibodies should be carried out on any patient who fails to respond to therapy. In short children born SGA, other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment. For SGA patients it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. In patients with increased risk for diabetes mellitus oral glucose tolerance testing should be performed. If overt diabetes occurs, growth hormone should not be administered. For SGA patients it is recommended to measure IGF-I level before start of treatment and twice a year thereafter. If on repeated measurements IGF-I levels exceed +2 SD compared to references for age and pubertal status, the IGF-I/IGFBP-3 ratio could be taken into account to consider dose adjustment. Experience in initiating treatment in SGA patients near onset of puberty is limited and therefore not recommended. Experience with SGA patients with Silver-Russel syndrome is limited. Some of the height gain obtained with treating short children born SGA with Somatropin may be lost if treatment is stopped before final height is reached. Cases of sleep apnoea and sudden death in paediatric patients with Prader-WilliSyndrome under treatment with Somatropin have been reported. Saizen is not indicated for treatment of paediatric patients with Prader-Willi-Syndrome, unless they have been diagnosed as GHD. Varying injection site can prevent lipoatrophy. In adults fluid retention is expected during somatropin therapy. In persistent oedema or severe paraesthesia, decrease the dosage in order to prevent carpal tunnel syndrome. Adult growth hormone deficiency should be treated as a lifelong condition. Experience is limited in patients over 60. Concomitant corticosteroid therapy may inhibit the response to somatropin. Side-effects: Antibodies to Somatropin can form in some patients, the clinical significance is unknown. Common side effects: Injection site reactions, localised lipoatrophy, fluid retention in adults (peripheral oedema, stiffness, joint swelling, arthralgia, myalgia, paresthesia), and headache (isolated). Serious: Hyperglycaemia, hypothyroidism, slipped capital femoral epiphysis, avascular necrosis of the femoral head, idiopathic intracranial hypertension. Please consult the Summary of Product Characteristics in relation to other side effects. Additional information is available on request. Legal Category: POM Basic NHS price: SAIZEN® 8mg click.easy®: Each carton contains 1 vial of SAIZEN® 8mg and 1 solvent cartridge. Cost: £185.44; SAIZEN 5.83 mg/ml and Saizen 8 mg/ml solution for injections Each carton contains either; 1 cartridge with 1.03ml of SAIZEN 5.83 mg/ml solution equivalent to 6.0mg. Cost: £139.0; 1 cartridge with 1.5ml of SAIZEN 8 mg/ml solution equivalent to 12.0mg. Cost: £278.16; 1 cartridge with 2.5ml of SAIZEN 8 mg/ml solution equivalent to 20.0mg. Cost: £463.60; Marketing Authorisation Holder and Numbers: SAIZEN® 8mg click.easy®: Serono Limited, Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, United Kingdom; PL 03400/0079, PA 285/5/4. Bacteriostatic solvent cartridge, PL 03400/0076. SAIZEN 5.83 mg/ml and Saizen 8 mg/ml solution for injections: MA Holder and Numbers for the UK: Serono Limited, Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, United Kingdom. Saizen 5.83 mg/ml: PL 03400/0087, Saizen 8 mg/ml: PL 03400/0088 MA Holder and Numbers for Ireland: Merck Serono Limited, Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, United Kingdom; Saizen 5.83 mg/ml: PA 654/18/1, Saizen 8 mg/ml: PA 654/18/2. For further information, including price queries, contact: UK: Merck Serono Ltd, Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, Tel: 020 8818 7373. Republic of Ireland: Merck Serono, 4045 Kingswood Road, Citywest Business Campus, Dublin 24, Tel: 01 4687590. Date of Preparation: May 2012 Adverse events should be reported and reporting forms and information can be found at www.mhra.gov.uk/yellowcard. In the Republic of Ireland information can be found at www.imb.ie. Adverse events should also be reported to Merck Serono Limited – Tel: +44 (0)20 8818 7373 or email: [email protected] 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes SAI12-0055 23 NOTES 24 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes NOTES 40th Meeting of the British Society for Paediatric Endocrinology and Diabetes 25 r British Society fo e th f o g n ti e e M 41st d Diabetes n a y g lo o in cr o d n Paediatric E e t a D e h t e v Sa K ome, Brighton, U 2013 | Brighton D 13-15 November . held for discussions will be presentations and s iou var the ere wh D 2013 and Hove and BSPE BSPED 2013. the city of Brighton to ical me lco we y art ies to present clin A he ample opportunit eting will provide crinology CME day on 13 me a do h en ton d wit gh an Bri nce e tes me Th be ric dia ogether will com ference will run research in paediat nities for The Brighton get-t mber, the main con and basic science o provide opportu On 14 and 15 Nove practice. It will als rse meetings, od Nu go t The British of alis as oss eci acr ide Sp s November 2013. re e nd and sha betes and Endocrin colleagues and frie will also h Dia ere wit the Th h ing ns. wit ork lively postsio h tw lel ses ral ne wit 3 r in pa in all the meeting and le conference dinne ations presented all 3 days. l also be a memorab gh wil ou with oral communic ere thr s Th s. ion Isle tat poster presen ent. be opportunities for dinner entertainm h Brighton when wit e lov in l fel Brighton beach, IV) rful and is noted for (later King George Brighton is vibrant and colou The Prince Regent his leisure time in rathon and also ton of ma gh ch Bri mu ton nt gh Bri spe ental tival, 1783. He cenic style with Ori r, Brighton Arts fes ara Pie he first visited in rsities, a medical o-S ton ive Ind gh un in Bri o on tw s ton Royal Pavili Parade. Brighton ha ence venue, Brigh de fer Pri con ton all look forward to e and constructed the gh Th We . . Bri tal ton the spi l residence in Brigh ated Children’s Ho gious arts dic sti de pre a a n is eve d d an interior as a Roya 20 an x l ple PED 13. schoo Royal Pavilion com eatre, rable meeting – BS Dome, is within the ng you for a memo nge and Pavilion Th mi cha lco Ex we rn Co ll, Ha Concert venue including a .uk www.bsped.org Conference Secretariat BioScientifica Ltd Euro House 22 Apex Court Contact: Conference Secretariat WoodlandsTel: +44 (0) 1454 642240 Bradley Stoke Fax: +44 (0) 1454 642222 Bristol Email: [email protected] BS32 4JTWebsite: www.bsped.org.uk